Immunotherapy and Immune Responses / CAR-T Cell Therapy Research / Virus-based Gene Therapy Research · Journal article

Tumor Immunotherapy Resistance: Underlying Mechanisms and Emerging Strategies to Overcome Therapeutic Bottlenecks

Oncology Communications · August 12, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review that synthesizes current understanding of immunotherapy resistance mechanisms and proposes combination therapy and personalized strategies as future directions. It does not present original data, test interventions, or provide evidence for practice recommendations—instead, it frames resistance as a problem requiring further investigation through TME profiling and biomarker-driven approaches.

What was studied

Narrative review. Patients with cancer receiving immunotherapy; no specific tumor type, stage, or population characteristics reported..

Key findings

Immunotherapies including antibody-based therapies, adoptive cell therapies, immune modulators, oncolytic viruses, and cancer vaccines commonly encounter resistance in clinical applications. Resistance mechanisms predominantly stem from tumor-intrinsic factors and tumor microenvironment (TME) factors. Combination therapies and personalized treatment strategies grounded in TME profiling and biomarkers are proposed as critical future directions.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This review identifies resistance as a barrier to immunotherapy efficacy and proposes a framework (TME profiling, biomarkers, combination therapy) to guide future research and clinical trials. Clinicians should view this as a conceptual roadmap rather than evidence for immediate practice change.

Plain-language summary

A narrative review synthesizing known resistance mechanisms and proposing future directions; raises questions about overcoming immunotherapy resistance but does not report original data or test interventions.

Study design

As stated by the source record.

MethodsNarrative review

Clinical bottom line

Caveats

No quantitative data, effect sizes, or comparative outcomes reported.
No systematic review methodology, PRISMA reporting, or explicit inclusion/exclusion criteria described.
Specific mechanisms and strategies are mentioned but not detailed or evidenced within the abstract.
No primary clinical trial data, patient cohorts, or experimental results provided to substantiate recommendations.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Systematic synthesis of literature; no primary data collection or experimental design reported.

Directness

limited

Review of mechanisms and strategies; no direct clinical or experimental evidence presented for specific interventions.

Consistency

insufficient

Source does not report comparative findings or discuss agreement or disagreement across studies.

Risk of bias

insufficient

Review article; no assessment of bias in included studies, selection criteria, or methodology reported.

Sample adequacy

insufficient

No primary data; no sample size or population studied in the review itself.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

This review presents a systematic synthesis of the principal tumor immunotherapy strategies and their corresponding resistance mechanisms. Immunotherapies—including antibody-based therapies, adoptive cell therapies, immune modulators, and novel approaches such as oncolytic viruses and cancer vaccines—work by stimulating or enhancing the patient's immune system to target cancer cells. Nevertheless, they commonly encounter resistance in clinical applications. Resistance mechanisms predominantly stem from tumor-intrinsic factors and tumor microenvironment (TME) factors. To surmount resistance, combination therapies and personalized treatment strategies grounded in TME profiling and biomarkers represent critical future directions.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Ziqing YuanImmunotherapy and Immune ResponsesCAR-T Cell Therapy ResearchVirus-based Gene Therapy ResearchChenxi ZhouShaoquan ZhengJieying Liang